AI Article Synopsis
- Evidence-based research on treating rare and severe skin diseases is lacking.
- Canakinumab and anakinra are drugs that target IL-1 pathways and are increasingly used for tough-to-treat skin conditions.
- The study aims to explore the various skin diseases that can potentially be treated with these medications.
Article Abstract
Evidence-based literature regarding management of rare and severe dermatologic disease is limited. Canakinumab and anakinra, two therapeutics used for inhibiting IL-1 pathways, have seen increased utilization for treatment of refractory dermatoses. We sought to better characterize the breadth of dermatologic conditions for which these medications could be utilized.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.36849/jdd.6154 | DOI Listing |
Publication Analysis
Top Keywords
dermatologic conditions
8
experience single
4
single academic
4
academic center
4
center il-1
4
il-1 inhibition
4
inhibition rare
4
rare dermatologic
4
conditions evidence-based
4
evidence-based literature
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!